Follicular bronchiolitis in an HIV-infected individual on combination antiretroviral therapy with low CD4+ cell count but sustained viral suppression.

A 36-year-old Danish man, living in Asia, was diagnosed with pneumonia (PCP) and HIV in 2013 (CD4+ count: 6 cells/µL; viral load: 518 000 copies/mL). He initiated combination antiretroviral therapy. Later that year, he was also diagnosed with granulomatosis with polyangiitis and was treated with prednisolone.

[Lamotrigine-induced pneumonitis].

A 28-year-old woman diagnosed with schizophrenia was admitted to hospital due to progressing dyspnoea for months. At admission, she was oxygen-dependent, and a high-resolution computed tomography revealed ground glass opacities. She had no obvious exposures besides having been treated with lamotrigine for several years.

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results.

Background: Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF).

Objective: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to target population, safety, adherence to the treatment and effect analysis in a well-characterised IPF population in a real-life setting.

Methods: Retrospective data collection from medical records of all patients in Denmark with IPF from 2011 to 2014.

[Working as a sandblaster can cause silicosis].

Silicosis is a common occupational disease worldwide. It is caused by the inhalation of crystalline silicon dioxide, i.e.

A case of unexplained hypoxemia.

We present a patient with acute-onset dyspnea and unexplained severe hypoxemia. No signs of severe cardiopulmonary disease, pulmonary arterial hypertension, or pulmonary embolism were present. The patient was diagnosed with hepatopulmonary syndrome, since liver disease of alcoholic origin was present, markedly increased alveolar-arterial oxygen difference existed, and intrapulmonary vascular dilations were demonstrated.

[Implementation of non invasive ventilation in respiratory ward in patients with exacerbations of chronic obstructive pulmonary disease].

Introduction: Non Invasive Ventilation (NIV) has been shown to lower the mortality rate from 22% to 9% when given as an additional treatment to selected chronic obstructive pulmonary disease (COPD) patients with acute respiratory failure and hypercapnia. Risk of intubation has been shown to fall from 33% to 14%. In February 2004 NIV was added as a treatment modality in a respiratory ward to patients with exacerbation of COPD after initial stabilization with standard treatment: oxygen, bronchodilators, systemic steroids and, if indicated, antibiotics.